HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VIGONVITA-B

125.100

+5.1004.25%

Volume:89.60K

Turnover:11.32M

Market Cap:20.97B

PE:-86.14

High:129.400

Open:121.000

Low:119.000

Close:120.000

52wk High:129.400

52wk Low:51.000

Shares:167.60M

HK Float Shares:66.68M

Volume Ratio:1.30

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.452

ROE:-132.51%

ROA:-18.15%

PB:123.87

PE(LYR):-86.14

PS:1565.18

Loading ...

Overview Company News Filings

Vigonvita Life Sciences (2630) Proposes Adoption of H Share Award Scheme

Bulletin Express

VIGONVITA-B Proposes Implementation of H-Share Incentive Scheme

Vigonvita Life Sciences Announces Proposed H Share Award Scheme

Vigonvita (02630) Reports No Change in Share Capital for January 2026

Bulletin Express

VIGONVITA-B (02630) Pulls Back Nearly 7% After Yesterday's 11% Surge on Nipah Virus Catalyst

Hong Kong Stock Movement | VIGONVITA-B (02630) Surged Over 14% to a Record High, Study Finds VV116 Has Therapeutic Potential Against Nipah Virus

Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications

Market Artistry in the First Month: VIGONVITA-B (02630) from "Cliff-like Plunge" to "V-shaped Reversal"?

Vigonvita Life Sciences' IPO Stabilization Period Ends With No Over-Allotment Exercise

MT Newswires Live

Vigonvita (2630) Announces Licensing Agreement with Simcere for VV116 Indications

Bulletin Express

Vigonvita Life Sciences (2630) Announces End of Stabilization Period and Over-Allotment Option Lapse

Bulletin Express

VIGONVITA-B (02630): Stabilization Period Concluded with No Price-Stabilizing Actions and Over-Allotment Option Lapsed

VIGONVITA-B (02630) Signs Licensing Agreement with SIMCERE PHARMA (02096) for New Indications of VV116

Vigonvita Life Sciences Co Ltd - Enters License Agreement With Simcere for Vv116

THOMSON REUTERS

Vigonvita Life Sciences Signs License Agreement With Simcere Pharmaceutical for VV116 New Indications

Vigonvita Life Sciences (02630) Announces Monthly Return for November 2025

Bulletin Express

VIGONVITA-B (02630) Proposes Full Circulation of H Shares

Vigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation

Bulletin Express

From Summit to Shared Success: FANGZHOU JIANKE (06086) and VIGONVITA-B (02630) Deepen Strategic Collaboration in "AI + Chronic Disease Management" to Build a Digital Future for Healthcare

Vigonvita Life Sciences Soars 185% in Hong Kong Debut

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02630/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02630\",,,,,undefined,":{"symbol":"02630","market":"HK","secType":"STK","nameCN":"VIGONVITA-B","latestPrice":125.1,"timestamp":1771574916533,"preClose":120,"halted":0,"volume":89600,"delay":0,"changeRate":0.042499999999999954,"floatShares":66677100,"shares":167597800,"eps":-1.452369,"marketStatus":"Market Closed","change":5.1,"latestTime":"02-20 16:08:36","open":121,"high":129.4,"low":119,"amount":11322560,"amplitude":0.086667,"askPrice":126,"askSize":400,"bidPrice":125.1,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.545571,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771810200000},"marketStatusCode":7,"adr":0,"listingDate":1762358400000,"exchange":"SEHK","adjPreClose":120,"openAndCloseTimeList":[[1771551000000,1771560000000],[1771563600000,1771574400000]],"volumeRatio":1.295661639723498,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02630\",,,,,undefined,":{"symbol":"02630","floatShares":66677100,"roa":"-18.15%","roe":"-132.51%","lyrEps":-1.452369,"volumeRatio":1.295661639723498,"shares":167597800,"dividePrice":0,"high":129.4,"amplitude":0.086667,"preClose":120,"low":119,"week52Low":51,"pbRate":"123.87","psRate":"1565.18","week52High":129.4,"institutionHeld":0,"latestPrice":125.1,"committee":-0.333333,"eps":-1.452369,"divideRate":0,"volume":89600,"delay":0,"ttmEps":-1.545571,"open":121,"prevYearClose":81.85,"prevWeekClose":110,"prevMonthClose":99.45,"prevQuarterClose":81.85,"fiveDayClose":111,"twentyDayClose":90.75,"sixtyDayClose":62.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02630\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02630\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02630","date":"2026-02-20","current":-80.94096,"percent":0,"low":-34.884005,"twenty":-27.587073,"median":-23.306067,"eighty":-19.674728,"high":-9.647367,"avg":-23.498136,"sd":4.570273,"marketCap":8341309338},"quantilePoints":[{"date":"2025-11-07","current":-19.090342,"twenty":-21.84559,"median":-19.090342,"eighty":-13.424557,"marketCap":4407358491},{"date":"2025-11-14","current":-19.641187,"twenty":-19.420849,"median":-16.095168,"eighty":-15.264414,"marketCap":4547380470},{"date":"2025-11-21","current":-17.28769,"twenty":-19.452561,"median":-18.09445,"eighty":-15.501254,"marketCap":4000627980},{"date":"2025-11-28","current":-20.095977,"twenty":-19.591091,"median":-19.037434,"eighty":-16.046947,"marketCap":4667399310},{"date":"2025-12-05","current":-22.096294,"twenty":-21.259546,"median":-19.451229,"eighty":-16.716837,"marketCap":5140806954},{"date":"2025-12-12","current":-20.997063,"twenty":-21.601599,"median":-19.578567,"eighty":-17.610394,"marketCap":4894101562},{"date":"2025-12-19","current":-23.416326,"twenty":-21.853997,"median":-20.095977,"eighty":-18.35497,"marketCap":5470858762},{"date":"2025-12-24","current":-23.9553,"twenty":-22.587001,"median":-20.380599,"eighty":-18.745749,"marketCap":5614214598},{"date":"2026-01-02","current":-23.818881,"twenty":-23.195416,"median":-20.975608,"eighty":-18.936771,"marketCap":5604213028},{"date":"2026-01-09","current":-24.028271,"twenty":-23.242124,"median":-21.499422,"eighty":-19.069179,"marketCap":5667556305},{"date":"2026-01-16","current":-25.359291,"twenty":-23.625318,"median":-21.781264,"eighty":-19.370201,"marketCap":6000941970},{"date":"2026-01-23","current":-26.793845,"twenty":-23.828886,"median":-22.096294,"eighty":-19.449016,"marketCap":6334327635},{"date":"2026-01-30","current":-27.921283,"twenty":-24.928673,"median":-22.61666,"eighty":-19.453005,"marketCap":6631040876},{"date":"2026-02-06","current":-29.544924,"twenty":-25.987891,"median":-22.879289,"eighty":-19.503447,"marketCap":7034437531},{"date":"2026-02-13","current":-30.629205,"twenty":-27.286118,"median":-23.1966,"eighty":-19.616139,"marketCap":7334484630},{"date":"2026-02-20","current":-34.884005,"twenty":-27.587073,"median":-23.306067,"eighty":-19.674728,"marketCap":8341309338}],"updateTime":1771738066218},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02630\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176271153","title":"Vigonvita Life Sciences (2630) Proposes Adoption of H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1176271153","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176271153?lang=en_us&edition=fundamental","pubTime":"2026-02-09 18:41","pubTimestamp":1770633686,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors passed a resolution on February 9, 2026 to propose an H Share Award Scheme. The plan is subject to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1197569309","title":"VIGONVITA-B Proposes Implementation of H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1197569309","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197569309?lang=en_us&edition=fundamental","pubTime":"2026-02-09 18:30","pubTimestamp":1770633017,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) has announced that on February 9, 2026, its Board of Directors passed a resolution to recommend the adoption of a share incentive scheme for the company. The Share Incentive...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"gpt_icon":0},{"id":"2610393106","title":"Vigonvita Life Sciences Announces Proposed H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2610393106","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610393106?lang=en_us&edition=fundamental","pubTime":"2026-02-09 18:24","pubTimestamp":1770632688,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co. Ltd. has announced the proposed adoption of an H Share Award Scheme. Under this plan, selected participants will be granted a specific number of H Shares as determined by the Board. The scheme is subject to shareholder approval, and the vesting date will be the date on which the entitlement to the relevant award is vested in the selected participant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLbLSbtG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"gpt_icon":0},{"id":"1116479819","title":"Vigonvita (02630) Reports No Change in Share Capital for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1116479819","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116479819?lang=en_us&edition=fundamental","pubTime":"2026-02-04 16:50","pubTimestamp":1770195008,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (02630) released its monthly return for the period ended 31 January 2026, confirming that the total authorized share capital remained at RMB 167,597,800. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1142758659","title":"VIGONVITA-B (02630) Pulls Back Nearly 7% After Yesterday's 11% Surge on Nipah Virus Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1142758659","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142758659?lang=en_us&edition=fundamental","pubTime":"2026-01-28 11:10","pubTimestamp":1769569833,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) retreated nearly 7%, following a significant surge of almost 11% yesterday. As of the time of writing, the stock was down 6.89%, trading at HKD 101.4, with a turnover of HKD...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e15c8a706660d4fff69f6a1942e8617d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"gpt_icon":0},{"id":"1172341760","title":"Hong Kong Stock Movement | VIGONVITA-B (02630) Surged Over 14% to a Record High, Study Finds VV116 Has Therapeutic Potential Against Nipah Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=1172341760","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172341760?lang=en_us&edition=fundamental","pubTime":"2026-01-27 10:48","pubTimestamp":1769482104,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) surged over 14% at one point, reaching a record high of HK$112.7. By the time of writing, the stock was up 12.02%, trading at HK$110, with a turnover of HK$12.9281 million. After...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e15c8a706660d4fff69f6a1942e8617d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"gpt_icon":0},{"id":"1183973139","title":"Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=1183973139","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183973139?lang=en_us&edition=fundamental","pubTime":"2025-12-17 13:48","pubTimestamp":1765950500,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","02630","BK1191","BK1583"],"gpt_icon":0},{"id":"1194182076","title":"Market Artistry in the First Month: VIGONVITA-B (02630) from \"Cliff-like Plunge\" to \"V-shaped Reversal\"?","url":"https://stock-news.laohu8.com/highlight/detail?id=1194182076","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194182076?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:56","pubTimestamp":1765457794,"startTime":"0","endTime":"0","summary":"In the technical analysis framework of capital markets, an extreme \"cliff-like\" plunge is often not the end of the story but may mark the beginning of a meticulously calculated restructuring of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1128","BK1191","01981"],"gpt_icon":0},{"id":"2588071328","title":"Vigonvita Life Sciences' IPO Stabilization Period Ends With No Over-Allotment Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2588071328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588071328?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:15","pubTimestamp":1764814521,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences  said the stabilization period for its global offering ended on Dec. 3, with no stabilizing actions taken, according to a Wednesday Hong Kong bourse filing.The company said there was no over-allocation of H shares in the international offering, and the overallotment option granted to the international underwriters lapsed unexercised on Dec. 3.No additional H shares were or will be issued.Vigonvita added that it continues to meet the public float requirement under listing rules.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"1155485645","title":"Vigonvita (2630) Announces Licensing Agreement with Simcere for VV116 Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=1155485645","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155485645?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:50","pubTimestamp":1764751814,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) has entered into a license agreement with Simcere Pharmaceutical Group Limited, granting Simcere Pharmaceutical exclusive rights in Greater China...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1108298578","title":"Vigonvita Life Sciences (2630) Announces End of Stabilization Period and Over-Allotment Option Lapse","url":"https://stock-news.laohu8.com/highlight/detail?id=1108298578","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108298578?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:48","pubTimestamp":1764751723,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司, Stock Code: 2630) announced that the stabilization period for its Global Offering concluded on December 3, 2025. According to the company, there...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1170505088","title":"VIGONVITA-B (02630): Stabilization Period Concluded with No Price-Stabilizing Actions and Over-Allotment Option Lapsed","url":"https://stock-news.laohu8.com/highlight/detail?id=1170505088","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170505088?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:44","pubTimestamp":1764751451,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) announced that the stabilization period for its global offering ended on December 3, 2025 (the 30th day after the deadline for the Hong Kong public offering application). No...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"gpt_icon":0},{"id":"1141237426","title":"VIGONVITA-B (02630) Signs Licensing Agreement with SIMCERE PHARMA (02096) for New Indications of VV116","url":"https://stock-news.laohu8.com/highlight/detail?id=1141237426","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141237426?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:36","pubTimestamp":1764750998,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) announced that it has entered into a licensing agreement with SIMCERE PHARMA Group Limited (02096) for new indications of VV116. Under the agreement, VIGONVITA-B will grant...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","02096","BK1583","BK1191"],"gpt_icon":0},{"id":"2588601621","title":"Vigonvita Life Sciences Co Ltd - Enters License Agreement With Simcere for Vv116","url":"https://stock-news.laohu8.com/highlight/detail?id=2588601621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588601621?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:30","pubTimestamp":1764750630,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X814P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02630"],"gpt_icon":0},{"id":"2588016085","title":"Vigonvita Life Sciences Signs License Agreement With Simcere Pharmaceutical for VV116 New Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2588016085","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588016085?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:30","pubTimestamp":1764750629,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co. Ltd. announced that it has entered into a license agreement with Simcere Pharmaceutical Group Limited. Under the agreement, Simcere Pharmaceutical will receive exclusive license rights for Vigonvita's drug candidate, deuremidevir hydrobromide , in the Greater China region for new indications, specifically for the treatment of infections caused by respiratory syncytial virus  and human metapneumovirus .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLDtMS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191","BK1583","02096"],"gpt_icon":0},{"id":"1106605876","title":"Vigonvita Life Sciences (02630) Announces Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1106605876","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106605876?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:24","pubTimestamp":1764714265,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (02630) published its monthly return as of 30 November 2025. The company’s total authorized share capital remained at RMB167,597,800, comprising 66,677,133 H shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1171471744","title":"VIGONVITA-B (02630) Proposes Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1171471744","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171471744?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:44","pubTimestamp":1764233051,"startTime":"0","endTime":"0","summary":"VIGONVITA-B (02630) announced on November 26, 2025, that its board of directors has considered and approved a proposal to implement the full circulation of H shares. The plan involves converting 100...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1168852122","title":"Vigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1168852122","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168852122?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:43","pubTimestamp":1764232990,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"gpt_icon":0},{"id":"1186764272","title":"From Summit to Shared Success: FANGZHOU JIANKE (06086) and VIGONVITA-B (02630) Deepen Strategic Collaboration in \"AI + Chronic Disease Management\" to Build a Digital Future for Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=1186764272","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186764272?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:10","pubTimestamp":1764123026,"startTime":"0","endTime":"0","summary":"On November 25, the FANGZHOU JIANKE (06086) Double 12 Core Partners Summit (hereafter referred to as the Partners Summit) was successfully held in Guangzhou. Centered on the theme \"Synergy for Shared...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","06086","BK1247"],"gpt_icon":0},{"id":"2581080771","title":"Vigonvita Life Sciences Soars 185% in Hong Kong Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2581080771","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581080771?lang=en_us&edition=fundamental","pubTime":"2025-11-06 10:13","pubTimestamp":1762395220,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences' (HKG:2630) shares opened 184.7% above its initial public offering price in a stellar Hong Kong debut on Thursday morning.The biopharmaceutical company opened at HK$95.00 per share, compared with the offer price of HK$33.37.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b49cf409b5b4e5e1ddffb226a99b8439","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02630"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}